DexCom, Inc. (NASDAQ:DXCM) Given Average Rating of “Moderate Buy” by Brokerages
Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ...
Flagship Harbor Advisors LLC Purchases Shares of 5,842 DexCom, Inc. (NASDAQ:DXCM)
Flagship Harbor Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) during the 4th quarter, ...
The Armenian Reporter1d
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Riverstone Advisors LLC
Riverstone Advisors LLC cut its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 14.0% in the fourth quarter, ...
Dementia risk may be lowered by one important medical device
New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms can overlap between diabetes and dementia.
GlobalData on MSN4d
Beta Bionics raises $204m to kickstart medtech IPO season
Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its ...
pharmaphorum4d
Real-time Abbott glucose monitor available to NHS after UK launch
The FreeStyle Libre 3 system consists of the sensor around ... Meanwhile, the UK launch of Freestyle Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 ...
drugdeliverybusiness2d
Trinity Biotech expects to submit ‘disruptive’ next-gen CGM to FDA in 2026
(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...
Fintel on MSN15h
Redburn Atlantic Upgrades DexCom (DXCM)
Fintel reports that on February 3, 2025, Redburn Atlantic upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to ...